



ITW

PATENT  
ATTORNEY DOCKET NO. 50304/111001

Certificate of Mailing: Date of Deposit: May 9, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine E. Fort

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ni et al.	Confirmation No.:	2018
Serial No.:	10/595,062	Art Unit:	Not Yet Assigned
Filed:	January 25, 2006	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	NECROSIS AVID TRACER AGENT		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on January 25, 2006, and that they have not yet received an initialed copy of the Form PTO-1449. Applicants thus request an initialed copy of the Form PTO-1449.

This statement is being filed before the receipt of a first Office action on the merits.


If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 5/9/2006

  
\_\_\_\_\_  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/111001
	Serial No.	10/595,062
	Applicant	Ni et al.
	Filing Date	January 25, 2006
	Group	Not Yet Assigned
	IDS Filed	May 9, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,013,241	01/11/2000	Marchal et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Ballester et al., "Indium-111-Monoclonal Antimyosin Antibody Studies After the First Year of Heart Transplantation. Identification of Risk Groups for Developing Rejection During Long-Term Follow-Up and Clinical Implications," <i>Circulation</i> 82:2100-2107 (1990).					
	Bormans et al., "Preparation, Analysis and Biodistribution in Mice of Iodine-123 Labelled Derivatives of Hypericin," <i>J. Label. Compd. Radiopharm.</i> 47:191-198 (2004).					
	Bremerich et al., "Microvascular Injury in Reperfused Infarcted Myocardium: Noninvasive Assessment with Contrast-Enhanced Echoplanar Magnetic Resonance Imaging," <i>J. Am. Coll. Cardiol.</i> 32:787-793 (1998).					
	Buja et al., "Sites and Mechanisms of Localization of Technetium-99m Phosphorus Radiopharmaceuticals in Acute Myocardial Infarcts and other Tissues," <i>J. Clin. Invest.</i> 60:724-740 (1977).					
	Chen et al., "Photodynamic Therapy with Hypericin in a Mouse P388 Tumor Model: Vascular Effects Determine the Efficacy," <i>Int. J. Oncol.</i> 18:737-742 (2001).					
	Choi et al., "Irreversibly Damaged Myocardium at MR Imaging with a Necrotic Tissue-Specific Contrast Agent in a Cat Model," <i>Radiology</i> 215:863-868 (2000).					
	Dec et al., "Antimyosin Antibody Cardiac Imaging: Its Role in the Diagnosis of Myocarditis," <i>J. Am. Coll. Cardiol.</i> 16:97-104 (1990).					
	Flotats and Carrió, "Non-Invasive In Vivo Imaging of Myocardial Apoptosis and Necrosis," <i>Eur. J. Nucl. Med. Mol. Imaging</i> 30:615-630 (2003).					
	Frist et al., "Noninvasive Detection of Human Cardiac Transplant Rejection with Indium-111 Antimyosin (Fab) Imaging," <i>Circulation</i> 76:V81-V85 (1987).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Attorney Docket No.	50304/111001
		Serial No.	10/595,062
		Applicant	Ni et al.
		Filing Date	January 25, 2006
		Group	Not Yet Assigned
		IDS Filed	May 9, 2006

	Herijgers et al., "Localization and Determination of Infarct Size by Gd-Mesoporphyrin Enhanced MRI in Dogs," <i>Int. J. Card. Imaging</i> 13:499-507 (1997).
	Khaw et al., "Specificity of Localization of Myosin-Specific Antibody Fragments in Experimental Myocardial Infarction. Histologic, Histochemical, Autoradiographic and Scintigraphic Studies," <i>Circulation</i> 60:1527-1531 (1979).
	Khaw et al., "Myocardial Injury: Quantitation by Cell Sorting Initiated with Antimyosin Fluorescent Spheres," <i>Science</i> 217:1050-1053 (1982).
	Khaw et al., "Scintigraphic Quantification of Myocardial Necrosis in Patients After Intravenous Injection of Myosin-Specific Antibody," <i>Circulation</i> 74:501-508 (1986).
	Khaw et al., "Acute Myocardial Infarct Imaging with Indium-111-Labeled Monoclonal Antimyosin Fab," <i>J. Nucl. Med.</i> 28:1671-1678 (1987).
	Khaw et al., "Avidity of Technetium 99m Glucarate for the Necrotic Myocardium: In Vivo and In Vitro Assessment," <i>J. Nucl. Cardiol.</i> 4:283-290 (1997).
	Khaw, "The Current Role of Infarct Avid Imaging," <i>Semin. Nucl. Med.</i> 29:259-270 (1999).
	Lavie et al., "The Chemical and Biological Properties of Hypericin — A Compound with a Broad Spectrum of Biological Activities," <i>Med. Res. Rev.</i> 15:111-119 (1995).
	Lee et al., "MR Imaging of Reperfused Myocardial Infarction: Comparison of Necrosis-Specific and Intravascular Contrast Agents in a Cat Model," <i>Radiology</i> 226:739-747 (2003).
	Lim and Choi, "MRI of Myocardial Infarction," <i>J. Magn. Reson. Imaging</i> 10:686-693 (1999).
	Marchal et al., "Paramagnetic Metalloporphyrins: Infarct Avid Contrast Agents for Diagnosis of Acute Myocardial Infarction by MRI," <i>Eur. Radiol.</i> 6:2-8 (1996).
	Mäurer et al., "Contrast-Enhanced High Resolution Magnetic Resonance Imaging of Pigmented Malignant Melanoma Using Mn-TPPS <sub>4</sub> and Gd-DTPA: Experimental Results," <i>Melanoma Res.</i> 10:40-46 (2000).
	Narula et al., "Recognition of Acute Myocarditis Masquerading as Acute Myocardial Infarction," <i>N Engl. J. Med.</i> 328:100-104 (1993).
	Narula et al., "Very Early Noninvasive Detection of Acute Experimental Nonreperfused Myocardial Infarction with <sup>99m</sup> Tc-Labeled Glucarate," <i>Circulation</i> 95:1577-1584 (1997).
	Nelson et al., "Metalloporphyrins as Tumor-Seeking MRI Contrast Media and as Potential Selective Treatment Sensitizers," <i>Invest. Radiol.</i> 25:S71-S73 (1990).
	Ni et al., "Localization of Metalloporphyrin-Induced 'Specific' Enhancement in Experimental Liver Tumors: Comparison of Magnetic Resonance Imaging, Microangiographic, and Histologic Findings," <i>Acad. Radiol.</i> 2:687-699 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/111001
	Serial No.	10/595,062
	Applicant	Ni et al.
	Filing Date	January 25, 2006
	Group	Not Yet Assigned
	IDS Filed	May 9, 2006

	Ni et al., "Paramagnetic Metalloporphyrins: From Enhancers of Malignant Tumors to Markers of Myocardial Infarcts," <i>Acad. Radiol.</i> 3:S395-S397 (1996).
	Ni et al., "Evaluation of Interventional Liver Tumor Ablation with Gd-Mesoporphyrin Enhanced Magnetic Resonance Imaging (Oral)," <i>Radiology</i> 205:319(757) (1997).
	Ni et al., "Magnetic Resonance Imaging — Histomorphologic Correlation Studies on Paramagnetic Metalloporphyrins in Rat Models of Necrosis," <i>Invest. Radiol.</i> 32:770-779 (1997).
	Ni et al., "Validation of Intracoronary Delivery of Metalloporphyrin as an In Vivo 'Histochemical Staining' for Myocardial Infarction with MR Imaging," <i>Acad. Radiol.</i> 5:S38-S41 (1998).
	Ni et al., "MRI Contrast Enhancement of Necrosis by MP-2269 and Gadophrin-2 in a Rat Model of Liver Infarction," <i>Invest. Radiol.</i> 36:97-103 (2001).
	Ni et al., "Occlusive Myocardial Infarction Enhanced or Not Enhanced with Necrosis-avid Contrast Agents at MR Imaging," <i>Radiology</i> 225:603-606 (2002).
	Obrador et al., "Active Myocardial Damage Without Attending Inflammatory Response in Dilated Cardiomyopathy," <i>J. Am. Coll. Cardiol.</i> 21:1667-1671 (1993).
	Obrador et al., "Presence, Evolving Changes, and Prognostic Implications of Myocardial Damage Detected in Idiopathic and Alcoholic Dilated Cardiomyopathy by 111In Monoclonal Antimyosin Antibodies," <i>Circulation</i> 89:2054-2061 (1994).
	Okada et al., "Early Detection of Infarct in Reperfused Canine Myocardium Using <sup>99m</sup> Tc-Glucarate," <i>J. Nucl. Med.</i> 45:655-664 (2004).
	Olmos et al., "High Sensitivity of Radiolabelled Antimyosin Scintigraphy in Assessing Anthracycline Related Early Myocyte Damage Preceding Cardiac Dysfunction," <i>Nucl. Med. Commun.</i> 23:871-877 (2002).
	Pass, "Photodynamic Therapy in Oncology: Mechanisms and Clinical Use," <i>J. Natl. Cancer Inst.</i> 85:443-456 (1993).
	Pislaru, "Noninvasive Measurements of Infarct Size After Thrombolysis with a Necrosis-Avid MRI Contrast Agent," <i>Circulation</i> 99:690-696 (1999).
	Rude et al., "Clinical Implications of the Technetium-99m Stannous Pyrophosphate Myocardial Scintigraphic 'Doughnut' Pattern in Patients with Acute Myocardial Infarcts," <i>Circulation</i> 59:721-730 (1979).
	Saeed et al., "Reperfused Myocardial Infarction as Seen with Use of Necrosis-Specific versus Standard Extracellular MR Contrast Media in Rats," <i>Radiology</i> 213:247-257 (1999).
	Wendland et al., "Contrast-Enhanced MRI for Quantification of Myocardial Viability," <i>J. Magn. Reson. Imaging</i> 10:694-702 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	